Diagnosis & Disease Information

Long-term results confirm that 4 courses of S-1 chemotherapy is inferior to the standard 8 courses in patients with stage II gastric cancer.

Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.

Combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/GEJ cancer, a phase 3 study suggests.

Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.

Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.

Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.